Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Vaimo Named One of Sweden’s Best Managed Companies in 2023 by Deloitte

Stockholm, Sweden, June 8, 2023 – Vaimo, a full-service omnichannel partner in digital commerce and experience, was chosen as one of Sweden’s Best Managed Companies in 2023 by Deloitte in cooperation with Nasdaq for the second consecutive year. This prestigious award acknowledges the outstanding success of private Swedish companies based on their ability to execute their vision, strategic direction, corporate culture, and financial performance. “We at Vaimo are honored to be named once again one of Deloitte’s Best Managed Companies,” expressed David Holender, CEO and Co-

SRV Group Plc: Managers' transactions – Tomi Yli-Kyyny

SRV GROUP PLC       MANAGERS' TRANSACTIONS   9 June 2023     10.05  EEST SRV Group Plc: Managers' transactions – Tomi Yli-Kyyny Notification under the EU Market Abuse Regulation, article 19 SRV Yhtiöt Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Tomi Yli-Kyyny Position: Member of the Board/Deputy member Issuer: SRV Yhtiöt Oyj LEI: 743700GB29FXC0VXF414 Notification type: INITIAL NOTIFICATION Reference number: 33164/5/4 ____________________________________________

Kemira Oyj: Members of the Nomination Board

Kemira Oyj, Stock Exchange Release, June 9, 2023 at 10.00 am (EEST)Kemira Oyj: Members of the Nomination Board  According to the decision of the Kemira Oyj’s Annual General Meeting, the Nomination Board consists of representatives of the four largest shareholders of Kemira Oyj as of May 31 preceding the Annual General Meeting and the Chair of the Board of Directors of the Company as an expert member.   Based on the ownership status of Kemira Oyj as of May 31, 2023, the shareholders represented in the Nomination Board are Oras Invest Oy, Solidium Oy, Impax Asset Management plc and

Sensys Gatso Group announces the timetable for the consolidation of shares and change of ticker symbol

At the annual general meeting of Sensys Gatso Group AB (publ) ("Sensys Gatso" or the "Company") on May 15th, 2023, it was decided to carry out a consolidation of shares at a ratio of 1:80, meaning that eighty (80) shares will be consolidated into one (1) new share. The meeting authorized the Board of Directors to determine the record date for the consolidation. In accordance with the decision of the annual general meeting, the Board of Directors of Sensys Gatso has determined that the record date shall be June 16th, 2023. The Company will also change its ticker symbol in connection with the

Safello enters into agreement with Januar for financial services

Stockholm, 9 June 2023 | Safello, the leading crypto exchange in the Nordics, enters into agreement with Januar to broaden the financial infrastructure on Safellos platform.  Januar, known for its innovative payment processing solutions, empowers businesses to accept multiple payment methods specializing in offering business accounts that seamlessly integrate decentralized finance solutions into traditional financial structures. Focusing on companies active within the digital asset space, allowing for EU crypto companies to leverage Januar's payment account solutions to accept payments

New biomarker data from BEXMAB study at EHA2023

Faron Pharmaceuticals Oy   (“Faron” or “the Company”)    Faron Announces New Biomarker Data from Phase I/II BEXMAB Study at EHA2023 Hybrid Congress · Bexmarilimab mode of action in AML/MDS supported with durable Clever-1 target engagement in bone marrow, with increases observed in T and NK cells and antigen presentation · Clinical activity across indications, with objective responses in 5 of 10 patients · Dose escalation ongoing, with initiation in 2H 2023 of Phase II in relapsed/refractory AML and MDS after failure on hypomethylating agents Press Release, June 9,

SRV Group Plc: Managers' transactions – Timo Kokkila

SRV GROUP PLC       MANAGERS' TRANSACTIONS   9 June 2023     10.00 EEST SRV Group Plc: Managers' transactions – Timo Kokkila Notification under the EU Market Abuse Regulation, article 19 SRV Yhtiöt Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Timo Kokkila Position: Member of the Board/Deputy member Issuer: SRV Yhtiöt Oyj LEI: 743700GB29FXC0VXF414 Notification type: INITIAL NOTIFICATION Reference number: 33163/4/4 ____________________________________________ Transaction

SRV Group Plc: Managers' transactions – Matti Ahokas

SRV GROUP PLC       MANAGERS' TRANSACTIONS   9 June 2023     09.55 EEST SRV Group Plc: Managers' transactions – Matti Ahokas Notification under the EU Market Abuse Regulation, article 19 SRV Yhtiöt Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Matti Ahokas Position: Member of the Board/Deputy member Issuer: SRV Yhtiöt Oyj LEI: 743700GB29FXC0VXF414 Notification type: INITIAL NOTIFICATION Reference number: 33160/4/4 ____________________________________________ Transaction

BioStock: Chordate’s treatment has effect on allergic rhinitis

A new Italian study shows that Chordate Medical’s treatment K.O.S has positive effects on allergic rhinitis. The treatment in combination with medication improves nasal airflow and decreases symptoms such as congestion, runny nose, itching, and sneezing. Dr Lino Di Rienzo Businco, lead investigator in the study, shared his thoughts on the K.O.S treatment in an interview with BioStock.Watch the interview at biostock.se: https://www.biostock.se/en/2023/06/chordates-treatment-has-effect-on-allergic-rhinitis/ This is a press release from BioStock - Connecting Innovation & Capital. https://

SRV Group Plc: Managers' transactions – Hannu Leinonen

SRV GROUP PLC       MANAGERS' TRANSACTIONS   9 June 2023     09.50 EEST SRV Group Plc: Managers' transactions – Hannu Leinonen Notification under the EU Market Abuse Regulation, article 19 SRV Yhtiöt Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Hannu Leinonen Position: Member of the Board/Deputy member Issuer: SRV Yhtiöt Oyj LEI: 743700GB29FXC0VXF414 Notification type: INITIAL NOTIFICATION Reference number: 33155/6/8 ____________________________________________

Navian Selected for Business Sweden's Scale-Up Programme, Catalyst

Navian is pleased to announce that we have been selected to be part of the esteemed Catalyst programme, managed by Business Sweden. This selection represents a significant milestone for Navian and reaffirms the company's commitment to revolutionising the real estate development industry through innovative digital solutions, while also propelling our plans for expanding our international presence.Catalyst  is a renowned programme designed to propel Swedish start-up companies towards

SRV Group Plc: Managers' transactions – Heli Iisakka

SRV GROUP PLC       MANAGERS' TRANSACTIONS   9 June 2023     09.45 EEST SRV Group Plc: Managers' transactions – Heli Iisakka Notification under the EU Market Abuse Regulation, article 19 SRV Yhtiöt Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Iisakka Heli Position: Member of the Board/Deputy member Issuer: SRV Yhtiöt Oyj LEI: 743700GB29FXC0VXF414 Notification type: INITIAL NOTIFICATION Reference number: 33158/4/4 ____________________________________________ Transaction

Focus on interoperability in a new offline payment white paper and webinar by Crunchfish and Lipis Advisors

The interest in offline solutions from central banks, commercial banks and payment system providers have skyrocketed in recent years. Crunchfish in partnership with Lipis Advisors are proud to announce the fourth white paper and webinar in the series “Enabling offline payments in an online world” with a focus on interoperability. Crunchfish in partnership with Lipis Advisors announced today the fourth white paper and webinar focused on offline payment Interoperability. The white paper will be released on June 15th on 12 noon CET / 15.30 IST with a follow-up webinar streamed live

Aker BP confirms oil discovery near Yggdrasil

Aker BP (OSE:AKRBP, OTCQX:AKRBF) has successfully completed the drilling of the Øst Frigg Beta/Epsilon exploration well in the Yggdrasil area. This marks the longest exploration well ever drilled on the Norwegian Continental Shelf and has resulted in a significant oil discovery.  The updated estimate of the discovery size is 53-90 million barrels of oil equivalent (mmboe), which is twice as large as the original pre-drill estimate and slightly larger than the preliminary estimates announced on 25 May.   The discovery, located in the Yggdrasil area, contributes to increasing the

Brain+ A/S announces the first day of trading for the new shares and warrants from its rights issue

COMPANY ANNOUNCEMENT Copenhagen, Denmark, June 9, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.Brain+ A/S (“Brain+” or “the Company”) informed June 6, 2023, that first day of trading in the new shares and warrants of

TF Bank: Monthly statistics May 2023

The total loan portfolio amounted to SEK 16,566 million at the end of May. Compared to May 2022, the loan portfolio has increased by 29 % in local currencies.  Month May-23 May-22 ChangeConsumer Lending   New lending, SEK million 547 586 -7 %Credit Cards   New lending, SEK million 922 436 111 %Ecommerce Solutions   Transaction volume*, SEK million 1,193 809 47 %  Cumulative for the year Jan-May 23 Jan-May 22 ChangeConsumer Lending   New lending, SEK million 2,710

SKF to phase out its own fossil gas use with a SEK 3 billion decarbonization investment frame

Gothenburg, 9 June 2023: SKF has decided to allocate SEK 3 billion to meet its energy and decarbonization goal by 2030, which is a key element of the Group’s strategy. The Group has also decided to ban any fossil fuel investments in its own operations, as well as to replace direct fossil gas use with renewable energy or approved non-fossil fuel alternatives by 2029. The SEK 3 billion investment frame is to be exclusively used to fund decarbonization activities, mainly energy efficiency and removal of fossil gas use for process and building heat, within the Group’s operations around the

Notification according to chapter 9, section 5 and 6 of the Securities Market Act: BlackRock Inc.’s holding in Metso

Metso Corporation’s stock exchange release on June 9, 2023, at 09:20 a.m. EESTMetso Corporation has received a notification, pursuant to Chapter 9, Section 5 and 6 of the Finnish Securities Markets Act, about a change in the shareholding of BlackRock, Inc. On June 7, 2023, BlackRock's holding in Metso’s shares exceeded the 5 percent threshold and amounted to 42,782,003 shares or 5.16 percent of total shares and votes. BlackRock's holding through financial instruments in Metso amounted to 1,469,175 shares, which corresponds to 0.17 percent of the total amount of Metso’s shares. On June 7,

nirsevimab recommended for infant RSV protection

9 June 2023 Nirsevimab unanimously recommended by FDA Advisory Committee for theprevention of RSV lower respiratory tract disease in infants If approved, nirsevimab would be the first preventive option specifically designed toprotect the broad infant population through its first RSV season Across all clinical endpoints, a single dose of nirsevimab delivered consistent andsustained efficacy against RSV disease vs placebo The US Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) has voted unanimously 21 to 0 that AstraZeneca and Sanofi's

Capsol Technologies AS – New name registered

Oslo, Norway, 09 June 2023The new name of the company, Capsol Technologies AS, has now been registeredwith the Norwegian Register of Business Enterprises.The ticker at Euronext Growth Oslo remains unchanged: CAPSL.For further information, please contact:Jan KiellandChief Executive Officer, Capsol Technologies+47 415 69 974jan.kielland@capsoltechnologies.comwww.capsoltechnologies.comTone BekkestadChief Marketing Officer, Capsol Technologies+47 412 92 013tone.bekkestad@capsoltechnologies.comwww.capsoltechnologies.comAbout Capsol TechnologiesCapsol Technologies

Proact recognised twice at NetApp UK and Ireland Awards

Proact, Europe's leading independent data centre and cloud services provider, has received two awards at the 2023 NetApp UK&I Awards event.The first award, Public Sector Partner of the Year, recognises Proact's outstanding partnership with NetApp  in delivering innovative solutions to healthcare and local authorities in UK and Ireland. This achievement highlights Proact’s commitment to meeting the unique needs and challenges faced by public sector organisations, ultimately benefiting the communities they serve. The second award, Net New Logo Partner of the Year,

Wyld Networks - Scaling up for bulk delivery - Mangold Insight Analysis

The virtual satellite network operator Wyld Networks ("Wyld") has replenished its order book which now totals approximately SEK 91.5 million, of which SEK 14.4 million relates to data revenue. In the first quarter of 2023, revenue was lower than expected of SEK 1.3 (4.0) million, which led to a revision of the full-year estimate. Mangold continues to estimate that the company will start delivering orders in volume during the third quarter of 2023. The company's costs are increasing at an expected pace and estimates remain unchanged for 2023. The company is estimated to be well

AstraZeneca agreement with Quell Therapeutics

09 June 2023 AstraZeneca announces agreement with Quell Therapeuticsto develop, manufacture and commercialiseengineered T-regulatory cell therapies for autoimmune diseases Collaboration focused on Type 1 Diabetes and Inflammatory Bowel Diseaseusing Quell's proprietary multi-modular T-regulatory cell engineering AstraZeneca has entered into an exciting collaboration, exclusive option and license agreement with Quell Therapeutics to develop multiple engineered T-regulator (Treg) cell therapies that have the potential to be curative in Type 1 Diabetes (T1D) and Inflammatory

There are no items matching the current filter
There are no more items matching the current filter
Back to top